Hormonal Factors in Women's Sexual Pain Disorders

Female Sexual Pain Disorders

Volumn , Issue , 2009, Pages 180-194

  Goldstein, Irwin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atrophic vaginitis (with or without urethral prolapse); Clinical measurement of sex steroids; Cytosine, adenine, and guanine nucleotides (CAGrepeats); Dehydroepiandrosterone sulphate (DHEA S); Estrogens progestins physiology and pathophysiology; Hormonal factors in women's sexual pain disorders; Provoked vestibulodynia (PVD); Sexual pain disorders; Sexual pain common with multifactorial pathophysiologies

Indexed keywords

EID: 84867576878     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444308136.ch28     Document Type: Chapter

References (142)

1. Weijmar SchultzW, Basson R, Binik Y, et al. (2005) Women's sexual pain and its management. The Journal of Sexual Medicine 2, 301-16.
2. Graziottin A, Leiblum SR. (2005) Biological and psychosocial pathophysiology of female sexual dysfunction during the menopausal transition. The Journal of Sexual Medicine 2, 133-45.
3. Pukall C, Kandyba K, Amsel R, et al. (2007) Effectiveness of hypnosis for the treatment of vulvar vestibulitis syndrome: a preliminary investigation. The Journal of Sexual Medicine 4, 417-25.
4. Mascherpa F, Bogliatto F, Lynch PJ, et al. (2007) Vulvodynia as a possible somatization disorder: more than just an opinion. The Journal of Reproductive Medicine 52, 107-10.
5. Bergeron S, Khalifé S, Glazer HI, et al. (2008) Surgical and behavioral treatments for vestibulodynia: two-and-one-half year follow-up and predictors of outcome. Obstetrics and Gynecology 111, 159-66.
6. Desrosiers M, Bergeron S,Meana M, et al. (2008) Psychosexual characteristics of vestibulodynia couples: partner solicitousness and hostility are associated with pain. The Journal of Sexual Medicine 5, 418-27.
7. Payne KA, Binik YM, Amsel R, et al. (2005) When sex hurts, anxiety and fear orient attention towards pain. European Journal of Pain 9, 427-36.
8. ReissingED,BinikYM,KhaliféS, et al. (2004) Vaginal spasm, pain, and behavior: an empirical investigation of the diagnosis of vaginismus. Archives of Sexual Behavior 33, 5-17.
9. Kandyba K, Binik YM. (2003) Hypnotherapy as a treatment for vulvar vestibulitis syndrome: a case report. Journal of Sex and Marital Therapy 29, 237-42.
10. Reissing ED, Binik YM, Khalifé S, et al. (2003) Etiological correlates of vaginismus: sexual and physical abuse, sexual knowledge, sexual self-schema,andrelationship adjustment. Journal of Sex and Marital Therapy 29, 47-59.
11. Binik YM, Reissing E, Pukall CF, et al. (2002) The female sexual pain disorders: genital pain or sexual dysfunction? Archives of Sexual Behavior 31, 425-29.
12. Bergeron S, Brown C, Lord MJ, et al. (2002) Physical therapy for vulvar vestibulitis syndrome: a retrospective study. Journal of Sex and Marital Therapy 28, 183-92.
13. Pukall CF, Binik YM, Khalifé S, et al (2002) Vestibular tactile and pain thresholds in women with vulvar vestibulitis syndrome. Pain 96, 163-75.
14. Bergeron S, Binik YM, Khalifé S, et al. (2001) A randomized comparison of group cognitive-behavioral therapy, surface electromyographic biofeedback, and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis. Pain 91, 297-306.
15. Binik YM, Pukall CF, Reissing ED, et al. (2001) The sexual pain disorders: a desexualized approach. Journal of Sex and Marital Therapy 27, 113-16.
16. Binik YM,Meana M, Berkley K, et al. (1999) The sexual pain disorders: is the pain sexual or is the sex painful? Annual Review of Sexual Research 10, 210-35.
17. Blaustein JD. (2008) Progesterone and progestin receptors in the brain: the neglected ones. Endocrinology 149, 2737-38.
18. Blaustein JD. (2008) Neuroendocrine regulation of feminine sexual behavior: lessons from rodent models and thoughts about humans. Annual Review of Psychology 59, 93-118.
19. Jyotika J, McCutcheon J, Laroche J, et al. (2007) Deletion of the Bax gene disrupts sexual behavior and modestly impairs motor function in mice. Developmental Neurobiology 67, 1511-19.
20. Molenda-Figueira HA,Williams CA,Griffin AL, et al. (2006) Nuclear receptor coactivators function in estrogen receptor-and progestin receptor-dependent aspects of sexual behavior in female rats. Hormones and Behavior 50, 383-92.
21. Turcotte JC,Hunt PJ, Blaustein JD. (2005) Estrogenic effects of zearalenone on the expression of progestin receptors and sexual behavior in female rats. Hormones and Behavior 47, 178-84.
22. Becker JB, Arnold AP, Berkley KJ, et al. (2005) Strategies and methods for research on sex differences in brain and behavior. Endocrinology 146, 1650-73.
23. Lonstein JS, Blaustein JD. (2004) Immunocytochemical investigation of nuclear progestin receptor expression within dopaminergic neurones of the female rat brain. Journal of Neuroendocrinology 16, 534-43.
24. Huang A, Yaffe K, Vittinghoff E, et al. (2008) The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women. American Journal ofObstetrics and Gynecology 198, 265.
25. van der Stege JG, Groen H, van Zadelhoff SJ, et al. (2008) Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 15, 23-31.
26. Cayan F, Dilek U, Pata O, et al. (2008) Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol+drospirenone and tibolone, on sexual function in healthy postmenopausal women. The Journal of Sexual Medicine 5, 132-38.
27. Giraldi A, Marson L, Nappi R, et al. (2004) Physiology of female sexual function: animal models. The Journal of Sexual Medicine 1, 237-53.
28. Traish AM, Kim N,Min K, et al. (2002) Role of androgens in female genital sexual arousal: receptor expression, structure, and function. Fertility and Sterility 77, S11-18.
29. PessinaMA,HoytRFJr., Goldstein I, et al. (2006) Differential effectsof estradiol, progesterone, and testosteroneonvaginal structural integrity. Endocrinology 147, 61-69.
30. Traish AM, KimSW, Stankovic M, et al. (2007) Testosterone increases blood flow and expression of androgen and estrogen receptors in the rat vagina.TheJournal of SexualMedicine 4, 609-19.
31. Pessina MA, Hoyt RF Jr, Goldstein I, et al. (2006) Differential regulation of the expression of estrogen, progesterone, and androgen receptors by sex steroid hormones in the vagina: immunohistochemical studies. The Journal of Sexual Medicine 3, 804-14.
32. Bachmann G, Lobo RA, Gut R, et al. (2008) Efficacy of lowdose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstetrics and Gynecology 111, 67-76.
33. Suckling J, Lethaby A, Kennedy R. (2006) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. 18, CD001500.
34. Castelo-Branco C, Cancelo MJ, Villero J, et al. (2005) Management of postmenopausal vaginal atrophy and atrophic vaginitis. Maturitas 15, S46-52.
35. Caruso S, Agnello C, Intelisano G, et al. (2005) Prospective studyonsexual behavior ofwomenusing 30mgethinylestradiol and 3 mg drospirenone oral contraceptive. Contraception 72, 19-23.
36. Berglund AL,NigaardL,Rylander E. (2002) Vulvar pain, sexual behavior, and genital infections in a young population: a pilot study. Acta Obstetricia et Gynecologica Scandinavica 81, 738-42.
37. Harlow BL, Vitonis AF, Stewart EG. (2008) Influence of oral contraceptive use on the risk of adult-onset vulvodynia. The Journal of Reproductive Medicine 53, 102-10.
38. Bouchard C, Brisson J, Fortier M, et al. (2002) Use of oral contraceptive pills and vulvar vestibulitis: a case-control study. American Journal of Epidemiology 156, 254-61.
39. Sjöberg I, Nylander Lundqvist EN. Vulvar vestibulitis in the north of Sweden: an epidemiologic case-control study. The Journal of Reproductive Medicine 42, 166-68.
40. Greenstein A, Ben-Aroya Z, Fass O, et al. (2007) Vulvar vestibulitis syndrome and estrogen dose of oral contraceptive pills. The Journal of Sexual Medicine 4, 1679-83.
41. Panzer C, Wise S, Fantini G, et al. (2006) Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction. The Journal of Sexual Medicine 3, 104-13.
42. Goldstein I. (2007) Current management strategies of the postmenopausal patient with sexual health problems. The Journal of Sexual Medicine 4, 235-53.
43. Goldstein I, Alexander JL. (2005) Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. The Journal of Sexual Medicine 2, 154-65.
44. Salonia A, Pontillo M, Nappi RE, et al. (2008) Menstrual cycle-related changes in circulating androgens in healthy womenwith self-reported normal sexual function. The Journal of Sexual Medicine 5, 854-63.
45. O'Connell K, Westhoff C. (2008) Pharmacology of hormonal contraceptives and acne. Cutis 81, 8-12.
46. Sitruk-Ware RL,Menard J, Rad M, et al. (2007) Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Contraception 75, 430-37.
47. White T, Ozel B, Jain JK, et al. (2006) Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception 74, 293-96.
48. Warnock JK, Clayton A, Croft H, et al. (2006) Comparison of androgens in women with hypoactive sexual desire disorder: those on combined oral contraceptives (COCs) vs. those not on COCs. The Journal of Sexual Medicine 3, 878-82.
49. Lee JS, Lacroix AZ,Wu L, et al. (2008) Associations of serum sex hormone-binding globulin and sex hormone concentrations with hip fracture risk in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 93, 1796-1803.
50. Shifren JL, Rifai N, Desindes S, et al. (2008) A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. Journal of Clinical Endocrinology and Metabolism 93, 1702-10.
51. Zähringer S, Tomova A, vonWerder K, et al. (2000) The influence of hyperthyroidism on the hypothalamic-pituitary-gonadal axis. Experimental and Clinical Endocrinology and Diabetes 108, 282-89.
52. Luppa PB, Thaler M, Schulte-Frohlinde E, et al. (2006) Unchanged androgen-binding properties of sex hormone-binding globulin in male patients with liver cirrhosis. Clinical Chemistry and Laboratory Medicine 44, 967-73.
53. Pascal N, Amouzou EK, Sanni A, et al. (2002) Serum concentrations of sex hormone binding globulin are elevated in kwashiorkor and anorexia nervosa but not in marasmus. American Journal of Clinical Nutrition 76, 239-44.
54. Isojärvi JI,Taubøll E,HerzogAG. (2005) Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs 19, 207-23.
55. Rosner W, Auchus RJ, Azziz R, et al. (2007) Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. Journal of Clinical Endocrinology and Metabolism 92, 405-13.
56. Shifren JL, Braunstein GD, Simon JA, et al. (2000; 2005) Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. New England Journal of Medicine 343, 682-88; 165, 1582-89.
57. Turpeinen U, Linko S, Itkonen O, et al. (2008) Determination of testosterone in serum by liquid chromatographytandem mass spectrometry. Scandinavian Journal of Clinical and Laboratory 68, 50-57.
58. Vermeulen A, Verdonck L, Kaufman JM. (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 84, 3666-72.
59. DeVan ML, Bankson DD, Abadie JM. (2008) To what extent are free testosterone (FT) values reproducible between the two Washingtons, and can calculated FT be used in lieu of expensive direct measurements?American Journal of Clinical Pathology 129, 459-63.
60. Rinaldi S, Geay A, Déchaud H, et al. (2002) Validity of free testosterone and free estradiol determinations in serumsamples from postmenopausal women by theoretical calculations. Cancer Epidemiology Biomarkers and Prevention 11, 1065-71.
61. Xita N, Georgiou I, Lazaros L, et al. (2008) The role of sex hormone-binding globulin and androgen receptor gene variants in the development of polycystic ovary syndrome. Human Reproduction 23, 693-98.
62. Labrie F, Bélanger A, Bélanger P, et al. (2006) Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. Journal of Steroid Biochemistry and Molecular Biology 99, 182-88.
63. Cappel M, Mauger D, Thiboutot D. (2005) Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Archives of Dermatology 141, 333-38.
64. Tosti A, Piraccini BM, Iorizzo M, et al. (2005) The natural history of androgenetic alopecia. Journal of Cosmetic Dermatology 4, 41-43.
65. Davison SL, Bell R, Donath S, et al. (2005) Androgen levels in adult females: changes with age, menopause, and oophorectomy. Journal of Clinical Endocrinology and Metabolism 90, 3847-53.
66. Guay A, Munarriz R, Jacobson J, et al. (2004) Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part . Serum androgen levels in women aged 20-49 years with no complaints of sexual dysfunction. International Journal of Impotence Research 16, 112-20.
67. Burger HG, Dudley EC,Cui J, et al. (2000) Aprospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. Journal of Clinical Endocrinology and Metabolism 85, 2832-38.
68. Labrie F, Bélanger A,Cusan L, et al. (1997) Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. Journal of Clinical Endocrinology and Metabolism 82, 2396-2402.
69. McTiernan A,Wu L, Barnabei VM, et al.;WHIInvestigators. (2008) Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels in postmenopausal women. Breast Cancer Research and Treatment 108, 217-31.
70. Zumoff B, Strain GW,Miller LK, et al. (1995) Twenty-fourhour mean plasma testosterone concentration declines with age in normal premenopausal women. Journal of Clinical Endocrinology and Metabolism 80, 1429-30.
71. Liu D, Si H, Reynolds KA, et al. (2007) Dehydroepiandrosterone protects vascular endothelial cells against apoptosis through a G α i protein-dependent activation of phosphatidylinositol 3-kinase/Akt and regulation of antiapoptotic Bcl-2 expression. Endocrinology 148, 3068-76.
72. Traish AM, Kim NN, Huang YH, et al. (2003) Sex steroid hormones differentially regulate nitric oxide synthase and arginase activities in the proximal and distal rabbit vagina. International Journal of Impotence Research 15, 397-404.
73. Traish AM, Huang YH,Min K, et al. (2004) Binding characteristics of [3H]delta(5)-androstene-3β,17β-diol to a nuclear protein in the rabbit vagina. Steroids 69, 71-78.
74. Bodo C, Rissman EF. (2008) The androgen receptor is selectively involved in organization of sexually dimorphic social behaviors in mice. Endocrinology.
75. Dakin CL, Wilson CA, Kalló I, et al. (2008) Neonatal stimulation of 5-HT(2) receptors reduces androgen receptor expression in the rat anteroventral periventricular nucleus and sexually dimorphic preoptic area. European Journal of Neuroscience 27, 2473-80.
76. Yague JG, Wang AC, Janssen WG, et al. (2008) Aromatase distribution in the monkey temporal neocortex and hippocampus. Brain Research 1209, 115-27.
77. Graziottin A, Leiblum SR. (2005) Biological and psychosocial pathophysiology of female sexual dysfunction during the menopausal transition. The Journal of Sexual Medicine 3, 133-45.
78. Taylor AH, Guzail M, Al-Azzawi F. (2008) Differential expression of oestrogen receptor isoforms and androgen receptor in the normal vulva and vagina compared with vulval lichen sclerosus and chronic vaginitis. British Journal of Dermatology 158, 319-28.
79. Hodgins MB, Spike RC, Mackie RM, et al. (1998) An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina. British Journal of Obstetrics and Gynaecology 105, 216-22.
80. Davis SR. (1999) The therapeutic use of androgens in women. Journal of Steroid Biochemistry and Molecular Biology 69, 177-84.
81. Braunstein GD. (2006) Androgen insufficiency in women. Growth Hormone and IGF Research 16, S109-117.
82. Rivera-WollLM,PapaliaM,Davis SR, et al. (2004) Androgen insufficiency in women: diagnostic and therapeutic implications. Human Reproduction Update 10, 421-32.
83. Bachmann G, Bancroft J, Braunstein G, et al. (2002) Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertility and Sterility 77, 660-65.
84. Santoro N, Torrens J, Crawford S, et al. (2005) Correlates of circulating androgens in midlife women: the study of women's health across the nation. Journal of Clinical Endocrinology and Metabolism 90, 4836-45.
85. Braunstein GD, Sundwall DA, Katz M, et al. (2005) Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo controlled trial. Archives of Internal Medicine 165, 1582-89.
86. Guay A, Jacobson J, Munarriz R, et al. (2004) Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part B: Reduced serum androgen levels inhealthy premenopausalwomenwith complaints of sexual dysfunction. International Journal of Impotence Research 16, 121-29.
87. Song YS, Yang HJ, Song ES, et al. (2008) Sexual function and quality of life in Korean women with chronic renal failure on hemodialysis: case-control study. Urology 71, 243-46.
88. TurnaB,Apaydin E, SemerciB, et al. (2005) Womenwith low libido: correlation of decreased androgen levels with female sexual function index. International Journal of Impotence Research 17, 48-53.
89. Davis SR, Davison SL, Donath S, et al. (2005) Circulating androgen levels and self-reported sexual function inwomen. Journal of the American Medical Association 294, 91-96.
90. Krassas GE,Tziomalos K,Papadopoulou F, et al. (2008) Erectile dysfunction in patientswith hyper-and hypothyroidism: how common and should we treat? Journal of Clinical Endocrinology and Metabolism 93, 1815-19.
91. Carani C, Isidori AM, Granata A, et al. (2005) Multicenter study on the prevalence of sexual symptoms in male hypoand hyperthyroid patients. Journal of Clinical Endocrinology and Metabolism 90, 6472-79.
92. Arlt W, Callies F, van Vlijmen JC, et al. (1999) Dehydroepiandrosterone replacement in women with adrenal insufficiency. New England Journal of Medicine 341, 1013-20.
93. Munarriz R, Talakoub L, Flaherty E, et al. (2002) Androgen replacement therapy with dehydroepiandrosterone for androgen insufficiency and female sexual dysfunction: androgen and questionnaire results. Journal of Sex andMarital Therapy 28, 165-73.
94. Baulieu EE, Thomas G, Legrain S, et al. (2000) Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Obstetrical and Gynecological Survey 55, 695.
95. Davis S, Papalia MA, Norman RJ, et al. (2008) Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Annals of InternalMedicine 148, 569-77.
96. Goldstat R, Briganti E, Tran J, et al. (2003) Transdermal testosterone therapy improveswell-being,mood, and sexual function in premenopausal women.Menopause 10, 390-98.
97. El-Hage G, Eden JA, Manga RZ. (2007) A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomizedwomenwith hypoactive sexual desire disorder. Climacteric 10, 335-43.
98. Kingsberg S, Shifren J,Wekselman K, et al. (2007) Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. The Journal of Sexual Medicine 4, 1001-8.
99. Kingsberg S. (2007) Testosterone treatment for hypoactive sexual desire disorder in postmenopausal women. The Journal of Sexual Medicine 4, 2.
100. Goldstein AT, Burrows L. (2008) Vulvodynia. The Journal of Sexual Medicine 5, 5-14.
101. Braunstein GD. (2007) Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies. The Journal of Sexual Medicine 4, 859-66.
102. Fenichel RM,WarrenMP. (2007) Anorexia, bulimia, and the athletic triad: evaluation and management. Current Osteoporosis Reports 5, 160-64.
103. Wessler S, Otto C,Wilck N, et al. (2006) Identification of estrogen receptor ligands leading toactivation of non-genomic signaling pathways while exhibiting only weak transcriptional activity. Journal of Steroid Biochemistry andMolecular Biology 98, 25-35.
104. Bakker J, Baum MJ. (2008) Role for estradiol in femaletypical brain and behavioral sexual differentiation. Frontiers in Neuroendocrinology 29, 1-16.
105. Blaustein JD. (2008) Neuroendocrine regulation of feminine sexual behavior: lessons from rodent models and thoughts about humans. Annual Review of Psychology 59, 93-118.
106. White MM, Sheffer I, Teeter J, et al. (2007) Hypothalamic progesteronereceptor-Amediates gonadotropin surges, selfpriming, and receptivity in estrogen-primed female mice. Journal of Molecular Endocrinology 38, 35-50.
107. Petralia SM, Frye CA. (2006) In the ventral tegmental area, cyclic AMP mediates the actions of progesterone at dopamine type 1 receptors for lordosis of rats and hamsters. Journal of Neuroendocrinology 18, 902-14.
108. Frye CA,Walf AA, Petralia SM. (2006) Progestins' effects on sexual behaviour of female rats and hamsters involving D1 andGABA(A) receptors in the ventral tegmental areamay be G-protein-dependent. Behavioral Brain Research 172, 286-93.
109. Molenda-Figueira HA,Williams CA,Griffin AL, et al. (2006) Nuclear receptor coactivators function in estrogen receptor-and progestin receptor-dependent aspects of sexual behavior in female rats. Hormones and Behavior 50, 383-92.
110. Frye CA,Walf AA,Petralia SM. (2006) Inthe ventral tegmental area, progestins have actions at D1 receptors for lordosis of hamsters and rats that involve GABA A receptors. Hormones and Behavior 50, 332-37.
111. Pazol K, Northcutt KV, Wilson ME, et al. (2006) Medroxyprogesterone acetate acutely facilitates and sequentially inhibits sexual behavior in female rats.Hormones and Behavior 49, 105-13.
112. LandryT,BergeronS,DupuisMJ, et al. (2008) The treatment of provoked vestibulodynia: a critical review. Clinical Journal of Pain 24, 155-71.
113. Johannesson U, Sahlin L, Masironi B, et al. (2008) Steroid receptor expression and morphology in provoked vestibulodynia. American Journal of Obstetrics and Gynecology 198, 311.
114. Green J, Hetherton J. (2005) Psychological aspects of vulvar vestibulitis syndrome. Journal of Psychosomatic Obstetrics and Gynecology 26, 101-6.
115. Reissing ED, Brown C, Lord MJ, et al. (2005) Pelvic floor muscle functioning in women with vulvar vestibulitis syndrome. Journal of Psychosomatic Obstetrics and Gynecology 26, 107.
116. Nyirjesy P. (2001) Chronic vulvovaginal candidiasis. American Family Physician 63, 697-702.
117. Bohm-Starke N, Hilliges M, Brodda-Jansen G, et al. (2001) Psychophysical evidence of nociceptor sensitization in vulvar vestibulitis syndrome. Pain 94, 177-83.
118. Babula O, Linhares IM, Bongiovanni AM, et al. (2008) Association between primary vulvar vestibulitis syndrome, defective induction of tumor necrosis factor-α, and carriage of the mannose-binding lectin codon 54 gene polymorphism. American Journal of Obstetrics and Gynecology 198, 101.
119. Babula O, Danielsson I, Sjoberg I, et al. (2004) Altered distribution of mannose-binding lectin alleles at exon I codon 54 in women with vulvar vestibulitis syndrome. American Journal of Obstetrics and Gynecology 191, 762-66.
120. Foster DC, Sazenski TM, Stodgell CJ. (2004) Impact of genetic variation in interleukin-1 receptor antagonist and melanocortin-1 receptor genes on vulvar vestibulitis syndrome. The Journal of Reproductive Medicine 49, 503-9.
121. Eva LJ, MacLean AB, Reid WM, et al. (2003) Estrogen receptor expression in vulvar vestibulitis syndrome. American Journal of Obstetrics and Gynecology 189, 458-61.
122. Sutherland S, Stankovic M, Cerda S, et al. (2004) Female sexual dysfunction secondary to sexual pain: androgen influence on the pathophysiology of vulvar vestibulitis syndrome. Podium #26. Presented to the Annual ISSWSHMeeting Oct 28-31, Atlanta.
123. ESHRE CapriWorkshopGroup. (2008) Intrauterine devices and intrauterine systems. Human Reproduction Update 14, 197-208.
124. Suckling J, Lethaby A, Kennedy R. (2006) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews 18, CD001500.
125. Castelo-Branco C, Cancelo MJ, Villero J, et al. (2005) Management of postmenopausal vaginal atrophy and atrophic vaginitis. Maturitas 52, S46-52.
126. Mainini G, Scaffa C, Rotondi M, et al. (2005) Local estrogen replacement therapy in postmenopausal atrophic vaginitis: efficacy and safety of low-dose 17β-estradiol vaginal tablets. Clinical and ExperimentalObstetrics andGynecology 32, 111-13.
127. Ballagh SA. (2005) Vaginal hormone therapy for urogenital and menopausal symptoms. Seminars in Reproductive Medicine 23, 126-40.
128. Greendale GA, Zibecchi L, Petersen L, et al. (1999) Development and validation of a physical examination scale to assess vaginal atrophy and inflammation. Climacteric 2, 197-204.
129. Kulp JL, Chaudhry S, Wiita B, et al. (2008) The accuracy of women performing vaginal pH self-testing. Journal ofWomens Health 17, 523-26.
130. Whiteside JL, Barber MD, Paraiso MF, et al. (2005) Vaginal rugae: measurement and significance. Climacteric 8, 71-75.
131. MunarrizR,TalakoubL,KuohungW, etal. (2002)Theprevalence of phimosis of the clitoris in women presenting to the sexual dysfunction clinic: lack of correlation to disorders of desire, arousal and orgasm. Journal of Sex andMarital Therapy 28, 18.
132. Ballagh SA. (2005) Vaginal hormone therapy for urogenital and menopausal symptoms.Seminars in Reproductive Medicine 23, 126-40.
133. Ouslander JG, Greendale GA, Uman G, et al. (2001) Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents. Journal of the American Geriatrics Society 49, 803-07.
134. Abouzeid H, Shergill IS, Al-Samarrai M. (2007) Successful medical treatment of advanced urethral prolapse. Journal of Obstetrics and Gynaecology 27, 634-35.
135. Society of Obstetricians and Gynaecologists of Canada. (2004) SOGC clinical practice guidelines. The detection and management of vaginal atrophy. International Journal of Gynaecology and Obstetrics 88, 222-28.
136. Crandall C. (2002) Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy. Journal ofWomen's Health 11, 857-877.
137. Santen RJ, Pinkerton JV,ConawayM, et al. (2002) Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 9, 179-87.
138. Manonai J, Theppisai U, Suthutvoravut S, et al. (2001) The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. Journal of Obstetrics and Gynaecology Research 27, 255-60.
139. Manonai J, Theppisai U, Chittacharoen A. (2001) Effect and safety of 17β-estradiol vaginal tablet in postmenopausal women with urogenital symptoms. Journal of the Medical Association of Thailand 84, 1015-20.
140. Taechakraichana N, Intraragsakul A,Panyakhamlerd K, et al. (1997) Estradiol and follicle-stimulating hormone levels in oophorectomized women using vaginal estrogen. Journal of the Medical Association of Thailand 80, 626-30.
141. Dew JE,Wren BG, Eden JA. (2003) A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 6, 45-52.
142. Kendall A, Dowsett M, Folkerd E, et al. (2006) Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Annals of Oncology 17, 584-87.